Post-doctoral position at Laboratory of Central and Peripheral Mechanisms of Neurodegeneration, Strasbourg University

A post-doctoral position is available at the Inserm Laboratory of Central and Peripheral Mechanisms of Neurodegeneration (UMR-S1118) team, to study the role of the hypothalamus in amyotrophic lateral sclerosis.The team has previously identified structural and functional deficits in the hypothalamus of ALS mouse models and patients (Vercruysse et al, Brain, 2016; Gorges, Vercruysse et al., JNNP, 2017; for review see Vercruysse et al, Frontiers, 2018) and identified alterations in selected neuronal types in the hypothalamus of mouse models. They now aim at using mouse genetics, combined with pharmacogenetics, to elucidate the contribution of these cell types in ALS and FTD pathophysiology.The project involves the characterisation of mutant mice at the molecular and cellular levels as well as motor phenotyping and energy metabolism.Applicants should hold a doctoral degree in Neuroscience. A solid experience in mouse behaviour and histology is required. The scientific expertise of the candidate should be documented by publications in international peer-reviewed journals. The 3-year position is available inOctober 2018.Applications should include a CV, a letter of intent including a statement of scientific experience and interests, and the names and contact information of two references.Please send your application as a single PDF toldupuis@unistra.fr with Postdoctoral position in the subject line.
Source: Society for Endocrinology - Category: Endocrinology Source Type: news

Related Links:

Conditions:   Amyotrophic Lateral Sclerosis;   Primary Lateral Sclerosis;   Kennedy's Disease Intervention:   Sponsors:   Assistance Publique - Hôpitaux de Paris;   Centre National de la Recherche Scientifique, France Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(AcuraStem, Inc.) AcuraStem, a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a 3.7 million dollar Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, 'AS2015', focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: 1 August 2018 Source:Neuroscience, Volume 384 Author(s): Maria Meyer, Agustina Lara, Hazel Hunt, Joseph Belanoff, E. Ronald de Kloet, Maria Claudia Gonzalez Deniselle, Alejandro F. De Nicola Wobbler mice are experimental models for amyotrophic lateral sclerosis. As such they show motoneuron degeneration, motor deficits, and astrogliosis and microgliosis of the spinal cord. Additionally, Wobbler mice show increased plasma, spinal cord and brain corticosterone levels and focal adrenocortical hyperplasia, suggesting a pathogenic role for glucocorticoids in this disorder. Considering this endocrine backgroun...
Source: Neuroscience - Category: Neuroscience Source Type: research
Conclusions: Empathy develops and operates within shared experiences and connections, enabled by structural possibilities provided by the forums giving users the opportunity and means to interact within public, restricted, and more private spaces, as well as within groups and in one-to-one exchanges. The atmosphere and feeling of both sites and perceived audiences were important facilitators of empathy, with users sharing a perception of virtual communities of caring and supportive people. Our findings are of value to organizations hosting health forums and to health professionals signposting patients to additional sources of support.
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
Publication date: July 2018 Source:Neurochemistry International, Volume 117 Author(s): Carlo Rodolfo, Silvia Campello, Francesco Cecconi Neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and Amyotrophic Lateral Sclerosis (ALS), are a complex “family” of pathologies, characterised by the progressive loss of neurons and/or neuronal functions, leading to severe physical and cognitive inabilities in affected patients. These syndromes, despite differences in the causative events, the onset, and the progression of the disease, share as common features ...
Source: Neurochemistry International - Category: Neuroscience Source Type: research
ò RS Abstract BACKGROUND: Amyotrophic Lateral Sclerosis flail arm (ALS-FA) is a motor neuron disease form confined to the upper limbs (cervical spinal cord region), often with asymmetric onset. To date, there is no defined neurorehabilitative strategy for ALS patients, although aerobic exercises may be of some help. CASE REPORT: A 69 year-old woman affected by ALS-FA was admitted to our research institute because of upper limb muscles weakness. She was then submitted to two different conventional physiotherapy programs, the first stand-alone and the second combined to a robotic treatment. The patient g...
Source: European Journal of Physical and Rehabilitation Medicine - Category: Rehabilitation Authors: Tags: Eur J Phys Rehabil Med Source Type: research
Conclusions: NF-L levels increased in CSF and serum of patients with ALS. NF-L may thus be a neurodegenerative biomarker for predicting ALS severity and progression, and the survival of patients with this disease.Neurodegener Dis
Source: Neurodegenerative Diseases - Category: Neurology Source Type: research
Boston-based Flex Pharma will lay off most of its employees and explore a potential sale or merger after ending a mid-stage trial of its lead drug, which targets several diseases including amyotrophic lateral sclerosis, or ALS. Flex (Nasdaq: FLKS) announced Wednesday that it had halted a Phase 2 study of the drug, called FLX-787, in patients with either ALS or neurological disorder Charcot-Marie-Tooth disease. The company cited “oral tolerability concerns,” though it said that the drug had helped…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Valosin-containing protein (VCP) is a ubiquitous protein, being broadly expressed in several human body systems [1]. More than 45 missense mutations in the VCP gene have been associated with several disease conditions, collectively known as ‘multisystem proteinopathies’: these include early-onset Paget disease of the bone (PDB), myopathy with rimmed vacuoles or inclusion body myopathy (IBM), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) [2, 3].. Myopathy is the most common clinical feature of these conditio ns, mainly affecting proximal muscles.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
Publication date: Available online 12 June 2018 Source:Stem Cell Research Author(s): Julia Higelin, Alberto Catanese, Lena Luisa Semelink-Sedlacek, Sertap Oeztuerk, Anne-Kathrin Lutz, Julia Bausinger, Gotthold Barbi, Günter Speit, Peter M. Andersen, Albert C. Ludolph, Maria Demestre, Tobias M. Boeckers Mutations in genes coding for proteins involved in DNA damage response (DDR) and repair, such as C9orf72 and FUS (Fused in Sarcoma), are associated with neurodegenerative diseases and lead to amyotrophic lateral sclerosis (ALS). Heterozygous loss-of-function mutations in NEK1 (NIMA-related kinase 1) have also been rece...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
More News: ALS | Brain | Endocrinology | Genetics | Laboratory Medicine | Neurology | Neuroscience | Study